These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 7738186)

  • 1. Generation of a drug resistance profile by quantitation of mdr-1/P-glycoprotein in the cell lines of the National Cancer Institute Anticancer Drug Screen.
    Alvarez M; Paull K; Monks A; Hose C; Lee JS; Weinstein J; Grever M; Bates S; Fojo T
    J Clin Invest; 1995 May; 95(5):2205-14. PubMed ID: 7738186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suppression of P-glycoprotein expression and multidrug resistance by DNA cross-linking agents.
    Ihnat MA; Lariviere JP; Warren AJ; La Ronde N; Blaxall JR; Pierre KM; Turpie BW; Hamilton JW
    Clin Cancer Res; 1997 Aug; 3(8):1339-46. PubMed ID: 9815817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen.
    Lee JS; Paull K; Alvarez M; Hose C; Monks A; Grever M; Fojo AT; Bates SE
    Mol Pharmacol; 1994 Oct; 46(4):627-38. PubMed ID: 7969041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines.
    Hamaguchi K; Godwin AK; Yakushiji M; O'Dwyer PJ; Ozols RF; Hamilton TC
    Cancer Res; 1993 Nov; 53(21):5225-32. PubMed ID: 8106143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of multidrug resistance in MOLT-4 cells by anticancer agents is closely related to increased expression of functional P-glycoprotein and MDR1 mRNA.
    Liu ZL; Onda K; Tanaka S; Toma T; Hirano T; Oka K
    Cancer Chemother Pharmacol; 2002 May; 49(5):391-7. PubMed ID: 11976833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multidrug-resistant phenotype of disease-oriented panels of human tumor cell lines used for anticancer drug screening.
    Wu L; Smythe AM; Stinson SF; Mullendore LA; Monks A; Scudiero DA; Paull KD; Koutsoukos AD; Rubinstein LV; Boyd MR
    Cancer Res; 1992 Jun; 52(11):3029-34. PubMed ID: 1350507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nuclear immunolocalization of P-glycoprotein in multidrug-resistant cell lines showing similar mechanisms of doxorubicin distribution.
    Baldini N; Scotlandi K; Serra M; Shikita T; Zini N; Ognibene A; Santi S; Ferracini R; Maraldi NM
    Eur J Cell Biol; 1995 Nov; 68(3):226-39. PubMed ID: 8603675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential effects of P-glycoprotein inhibitors on NIH3T3 cells transfected with wild-type (G185) or mutant (V185) multidrug transporters.
    Cardarelli CO; Aksentijevich I; Pastan I; Gottesman MM
    Cancer Res; 1995 Mar; 55(5):1086-91. PubMed ID: 7866993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship of multidrug resistance to rhodamine-123 selectivity between carcinoma and normal epithelial cells: taxol and vinblastine modulate drug efflux.
    Brouty-Boyé D; Kolonias D; Wu CJ; Savaraj N; Lampidis TJ
    Cancer Res; 1995 Apr; 55(8):1633-8. PubMed ID: 7712466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Stemona curtisii root extract on P-glycoprotein and MRP-1 function in multidrug-resistant cancer cells.
    Limtrakul P; Siwanon S; Yodkeeree S; Duangrat C
    Phytomedicine; 2007 Jun; 14(6):381-9. PubMed ID: 17467965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New silicon compounds as resistance modifiers against multidrug-resistant cancer cells.
    Molnar J; Mucsi I; Nacsa J; Hevér A; Gyémánt N; Ugocsai K; Hegyes P; Kiessig S; Gaal D; Lage H; Varga A
    Anticancer Res; 2004; 24(2B):865-71. PubMed ID: 15161039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of non-cross-resistant platinum compounds with novel cytotoxicity profiles using the NCI anticancer drug screen and clustered image map visualizations.
    Fojo T; Farrell N; Ortuzar W; Tanimura H; Weinstein J; Myers TG
    Crit Rev Oncol Hematol; 2005 Jan; 53(1):25-34. PubMed ID: 15607933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quinoline derivative KB3-1 potentiates paclitaxel induced cytotoxicity and cycle arrest via multidrug resistance reversal in MES-SA/DX5 cancer cells.
    Koo JS; Choi WC; Rhee YH; Lee HJ; Lee EO; Ahn KS; Bae HS; Ahn KS; Kang JM; Choi SU; Kim MO; Lu J; Kim SH
    Life Sci; 2008 Nov; 83(21-22):700-8. PubMed ID: 18845169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of the MRP and MDR1 multidrug resistance genes in small cell lung cancer.
    Campling BG; Young LC; Baer KA; Lam YM; Deeley RG; Cole SP; Gerlach JH
    Clin Cancer Res; 1997 Jan; 3(1):115-22. PubMed ID: 9815546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro evaluation of new anticancer drugs, exemplified by vinorelbine, using the fluorometric microculture cytotoxicity assay on human tumor cell lines and patient biopsy cells.
    Fridborg H; Nygren P; Dhar S; Csoka K; Kristensen J; Larsson R
    J Exp Ther Oncol; 1996 Sep; 1(5):286-95. PubMed ID: 9414416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reversal of multidrug resistance by small interfering double-stranded RNAs in ovarian cancer cells.
    Zhang T; Guan M; Jin HY; Lu Y
    Gynecol Oncol; 2005 May; 97(2):501-7. PubMed ID: 15863151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medroxyprogesterone-acetate reverses the MDR phenotype of the CG5-doxorubicin resistant human breast cancer cell line.
    Zibera C; Gibelli N; Maestri L; Della Cuna GR
    Anticancer Res; 1995; 15(3):745-9. PubMed ID: 7645952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of doxorubicin resistant rat prostate cancer cell lines.
    Replogle-Schwab TS; Schwab ED; Pienta KJ
    Anticancer Res; 1997; 17(6D):4535-8. PubMed ID: 9494564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Downregulation of JNK/SAPK activity is associated with the cross-resistance to P-glycoprotein-unrelated drugs in multidrug-resistant FM3A/M cells overexpressing P-glycoprotein.
    Kang CD; Ahn BK; Jeong CS; Kim KW; Lee HJ; Yoo SD; Chung BS; Kim SH
    Exp Cell Res; 2000 Apr; 256(1):300-7. PubMed ID: 10739677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
    Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
    Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.